Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Salivary Gland Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Tongue Neoplasms 5Rectal Neoplasms 3Pancreatic Neoplasms 3Esthesioneuroblastoma, Olfactory 3Colonic Neoplasms 3Carcinoma, Squamous Cell 3Pharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tonsillar Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Parotid Neoplasms 1Paranasal Sinus Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1

Interventions

cemiplimab 1advexin 1Erlotinib Hydrochloride 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma in Situ × Erlotinib Hydrochloride × Head & Neck × Clear all
NCT00402779 2020-04-21

Erlotinib Prevention of Oral Cancer (EPOC)

M.D. Anderson Cancer Center

Phase 3 Completed
303 enrolled 11 charts
Head & Neck

Carcinoma in Situ, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡